CFH and benign prostatic hyperplasia: In that study, promising candidate biomarkers, such as thrombospondin-1 (THBS1), tissue inhibitor of metalloproteinase 1 (TIMP-1), complement factor H (CFH), and prolow-density lipoprotein receptor-related protein 1 (LRP-1), were further validated by quantitative selected reaction monitoring (SRM) and ELISA in the sera of PCa and BPH patients [22].